9 Indispensable Attributes For The Staurosporine

Berthet,2 http://www.selleckchem.com/products/epz-5676.html J. Bastie,1 R. Casasnovas.1 1Hematology Clinic, CHU Le Bocage, Dijon, France; 2Medicine Nucleaire, Centre G.F. Leclerc, Dijon, France. Introduction: PET performed after two cycles of chemotherapy could predict outcome of Hodgkin lymphoma (HL) patients (pts) (Gallamini 2007), but suitable criteria to interpret interim PET (iPET) remain to be established. A visual analysis (VA) using a 5-point scale (5PS) was proposed to assess iPET response. However, SUV may improve iPET accuracy, and SUV reduction between baseline and iPET was shown to be superior to VA in patients (pts) with diffuse large B-cell lymphoma (Casasnovas 2011). To compare the clinical usefulness of both methods in HL pts, we analyzed iPET according to visual and SUV criteria in a retrospective single centre study. Methods: From 2007 to 2010, 59 pts http://www.selleck.cn/products/Staurosporine.html with a first diagnosis of HL were treated in our institution with four to eight cycles of either ABVD (85%) or BEACOPP. Radiotherapy was performed in 14 responding pts with localized disease. PET was carried out at baseline (PET0) and after two cycles of chemotherapy (PET2), and treatment was not modified according to PET2 result. PET scans were interpreted using the 5PS (PET2 positivity for 5PS score 4 or 5). Standard uptake value (SUVmax) reduction values between PET0 and PET2 (��SUV) were available for all pts, and pts with a ��SUV >71% (receiver operating characteristic curve) were considered as good responders. Median follow-up was 47?months (6�C71). Results: Using VA, 46 (78%) pts achieved a negative PET2, and 7 of them failed to treatment [negative predictive value (NPV)?=?85%]. Forty-nine (83%) pts had a ��SUV >71%, and 6 of them failed to treatment (NPV?=?88%). PET2 positive http://www.selleckchem.com/products/ly2109761.html predictive value was significantly better for ��SUV (70%) compared with VA (46%). Using ��SUV analysis, 6 (46%) of the 13 PET2 positive pts could be reclassified as good responder. While visual PET2 positivity was related to a lower 4-year progression-free survival (PFS) (45%) compared with PET2 negativity (81%, p?71 vs ��71%) was more accurate to identify pts with different 4-year PFS (82% vs 30%; p?